[Changes of blood pressure, pulse and electrolytes following long-term treatment of Parkinsonism using Ro 8-0576 (L-Dopa and decarboxylase inhibitor)].
D000368:Aged; D000978:Antiparkinson Agents / Q000494:pharmacology*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D001794:Blood Pressure / Q000187:drug effects*; D001795:Blood Pressure Determination; D002118:Calcium / Q000097:blood; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D002712:Chlorides / Q000097:blood; D004338:Drug Combinations; D004573:Electrolytes / Q000097:blood*; D005260:Female; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D007980:Levodopa / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy; D011188:Potassium / Q000097:blood; D011674:Pulse / Q000187:drug effects*; D012964:Sodium / Q000097:blood
D000978:Antiparkinson Agents; D002712:Chlorides; D004338:Drug Combinations; D004573:Electrolytes; D007980:Levodopa; D012964:Sodium; D002262:Carboxy-Lyases; D011188:Potassium; D002118:Calcium
Blutdruck-, Puls- und Elektrolytveränderungen bei einer Langzeitbehandlung von Parkinsonkranken mit Ro 8-0576 (L-Dopa und Decarboxylasehemmer)